Evommune (EVMN) EBIT Margin (2025)
Evommune (EVMN) reported EBIT Margin of 133.28% for Q3 2025, up 73.4% on a QoQ basis from 501.07% in Q1 2025.
Evommune (EVMN) has 1 years of EBIT Margin data on file, last reported at 133.28% in Q3 2025.
- Quarterly EBIT Margin changed N/A year-over-year to 133.28% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 631.0% (changed N/A YoY) and the FY2025 annual result came in at 623.62%, up 37656.0% from the prior year.
- EBIT Margin climbed to 133.28% in Q3 2025 per EVMN's latest filing, from 501.07% in the prior quarter.
- Across five years, EBIT Margin topped out at 133.28% in Q3 2025 and bottomed at 501.07% in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -133.28% |
| Mar 31, 2025 | -501.07% |